Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 7, 2008, Pages 728-734

  O'Brien, Mary E R ^a   Socinski, Mark A ^b   Popovich, Alexander Y ^c   Bondarenko, Igor N ^d   Tomova, Antoaneta ^e   Bilynsky, Borys T ^f   Hotko, Yevhen S ^g   Ganul, Valentin L ^h   Kostinsky, Ippolit Y ⁱ   Eisenfeld, Amy J ^j   Sandalic, Larissa ^j   Oldham, Fred B ^j   Bandstra, Bruce ^j   Sandler, Alan B ^k   Singer, Jack W ^j,l  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DONETSK MEDICAL UNIVERSITY   (Ukraine)

^d Dnipropetrovsk State Medical Academy   (Ukraine)

^e Regional Oncology Dispensary   (Bulgaria)

^f DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^g UZHGOROD NATIONAL UNIVERSITY   (Ukraine)

^h STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

ⁱ IVANO FRANKIVSK NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^j Cell Therapeutics Inc   (United States)

^k VANDERBILT INGRAM CANCER CENTER   (United States)

^l NONE   (United States)

more..

Author keywords

CT 2103; Non small cell lung cancer; Paclitaxel poliglumex; PPX; PS 2; Toxicity

Indexed keywords

GEMCITABINE; NARCOTIC ANALGESIC AGENT; NAVELBINE; PACLITAXEL POLIGLUMEX; PPX; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PACLITAXEL; POLYGLUTAMIC ACID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT REDUCTION; LUNG TUMOR; MIDDLE AGED; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; POLYGLUTAMIC ACID; SURVIVAL RATE;

EID: 50349101826     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31817c6b68     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults - United States, 2002. MMWR Morb Mortal Wkly Rep 2004;53:427-431.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-485.
3. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245-258.
4. National Cancer Institute: Non-small Cell Lung Cancer (PDQ): Treatment. May 1, 2007. Available at: http://www.nci.nih.gov/cancertopics/ pdq/treatment/non-small-cell-lung/healthprofessional. Accessed September 17, 2007.
5. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
6. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23:190 -196.
7. Perrone F, Di Maio M, Gallo C, et al. Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 2004;22:5018-5020.
8. Blackhall FH, Bhosle J, Thatcher N. Chemotherapy for advanced non- small cell lung cancer patients with performance status 2. Curr Opin Oncol 2005;17:135-139. 9. Langer CJ. Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax). Oncologist 2004;9:398-405.
9. Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001;12:1667-1670.
10. Ettinger D, Johnson B. Update: NCCN small cell and non-small cell lung cancer clinical practice guidelines. J Natl Compr Canc Netw 2005;3 (Suppl 1):S17-S21.
11. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-3137.
12. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
13. Singer JW. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromo-lecular taxane. J Control Release 2005;109:120-126.
14. Bernareggi A, Oldham FB, Besman M, et al. XYOTAX (paclitaxel poliglumex, PPX): tumor accumulation and prolonged exposure to paclitaxel [abstract]. Presented at the 11th World Conference on Lung Cancer, Barcelona, Spain, July 3-6 2005.
15. Rothmann M, Li N, Chen G, et al. Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003;22:239-264.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Kosmidis PA, Dimopoulis MA, Syrigos C. Gemcitabine (G) vs gemcit-abine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group [abstract]. J Clin Oncol 2004;22:7058.
18. Neubauer MA, Reynolds CH, Joppert MG, et al. Results of a phase II trial of gemcitabine in patients with non-small cell lung cancer and a performance status of 2. Clin Lung Cancer 2005;6:245-249.